Single Product, Single Price: Medicare Will Include All Versions Of Active Ingredient For Negotiation
Executive Summary
The US Medicare agency intends to treat all dosage forms of the same active ingredient as a single drug for purposes of its new price negotiation authority. The approach will have implications for product branding and line extension strategies.
You may also be interested in...
Medicare Negotiated Prices: CMS Seeking Private Sector Input On Implementation At Point Of Sale
Agency issues a request for information on establishing a “Medicare Transaction Facilitator” function at the pharmacy counter. CMS wants point of sale processes to ensure negotiated prices go only to eligible beneficiaries and that there is no duplication with 340B discounts, two concerns for manufacturers.
Piling On: AstraZeneca Files Sixth Manufacturer Lawsuit Against Medicare Negotiation Program
Firm leans into allegations that the US government violated the Administrative Procedures Act in implementing the program. More legal actions are expected from industry once CMS announces the first list of drugs subject to negotiation. Our lawsuit tracker will keep you apprised.
Piling On: AstraZeneca Files Sixth Manufacturer Lawsuit Against Medicare Negotiation Program
Firm leans into allegations that the US government violated the Administrative Procedures Act in implementing the program. More legal actions are expected from industry once CMS announces the first list of drugs subject to negotiation. Our lawsuit tracker will keep you apprised.